The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile
Latest Information Update: 22 Jul 2024
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Regorafenib (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms FINPROVE
- 30 Dec 2021 Status changed from not yet recruiting to recruiting.
- 23 Dec 2021 New trial record